LRRK2 and Parkinson disease: In this study, our primary objectives were to investigate the therapeutic efficacy of FL090, a novel small‐molecule LRRK2 kinase inhibitor, in mitigating the motor disability and neurodegeneration associated with PD without LRRK2 mutation.